Preauthorization required for covered transplants

Kidney transplants (living or deceased donor) and pancreas transplants (including simultaneous kidney/pancreas and pancreas alone in specified indications) are considered medically necessary for selected candidates and therefore require preauthorization consistent with plan benefit variations.

Follow listed procedure & diagnosis codes for coverage review

Procedure and diagnosis codes listed in the policy are associated with services 'Covered when medically necessary'; prior authorization and coverage determinations should follow member benefit terms and medical necessity review.

• Procedure codes listed under 'Covered when medically necessary' (see policy coding table).
• Diagnosis codes listed under 'Covered when medically necessary' (see policy coding table).

Prior authorization details not specified in these sections

The provided document sections reference OPTN policies and the CMS NCD but do not specify a detailed prior authorization code list or other granular prior authorization steps in these chunks.

No step‑therapy required before listing

No step‑therapy sequencing is specified in the policy text; evaluation for transplant may begin prior to dialysis initiation based on anticipated wait time.

• Listing consideration may begin before GFR ≤20 mL/min or dialysis initiation when appropriate.

Unlabeled inventory entry — verify local requirements

Provider attention: an inventory entry in the brief has no label or text; confirm there are no additional plan‑specific prior authorization or coding instructions beyond those in the policy.

No step‑therapy requirements in referenced content

Reiteration: these chunks do not describe any required step‑therapy prior to transplant evaluation or listing.

Document GFR and dialysis initiation for waitlist timing

Document renal function (e.g., GFR or measured/estimated creatinine clearance) and the date dialysis was initiated, as these factors are used for waitlist timing and priority assessment.

• Record GFR or creatinine clearance values (earliest date ≤20 mL/min used for wait time calculations).
• Document date regular dialysis was initiated for ESRD.

Coding listed is not definitive for coverage

Coding lists in the policy may not be exhaustive and the presence of a code in the document does not by itself guarantee coverage; coverage is determined by member benefit terms and medical necessity review.

• Use policy rules and member benefits to determine coverage, not code listing alone.

Policy history documents coding review; no extra PA history here

Policy history notes coding was reviewed during prior updates but these chunks do not provide additional provider documentation or prior authorization history details.

No additional explicit denial triggers stated here

These referenced chunks do not state explicit denial triggers beyond the contraindications and futility language elsewhere in the policy.

Contraindications remain potential denial triggers

Potential contraindications previously listed in the policy (see contraindications callout) may lead to denial; providers should assess and document these conditions during evaluation.

Perform comprehensive prelisting evaluation (GFR, dialysis, comorbidities)

Evaluation should include assessment of kidney function (GFR), dialysis status, comorbid disease assessment to determine futility risk, and psychosocial/substance‑use evaluation prior to listing.

• Assess GFR and document creatinine clearance when available.
• Assess dialysis status and date of initiation.
• Evaluate comorbid conditions that could make transplant futile or unsafe.
• Perform psychosocial and substance‑use assessment for adherence risk.

Follow OPTN/CMS guidance for evaluation; policy cites registries

The policy references national guidance and registry sources (OPTN/UNOS, CMS) as informing evaluation but does not enumerate a separate, exhaustive preapproval workup in these chunks.

Use cited evidence and OPTN/CMS resources for selection guidance

Cited literature and registry resources support outcomes and retransplantation considerations; providers should rely on OPTN and CMS resources as needed for detailed evaluation and selection criteria.

Center judgment required for candidate suitability

Transplant center judgment determines candidate suitability and potential contraindications; the policy references Blue Distinction and certification resources but does not mandate specific center‑level volume or accreditation requirements in these chunks.

• Transplant center evaluation of individual risks and contraindications is required.
• References to Blue Distinction and CMS certification imply reliance on certified centers but do not add explicit certification requirements in these sections.

Ensure evaluation by an appropriate transplant center

Transplant center judgment and certification considerations are emphasized; providers should ensure candidate evaluation is performed by an appropriate transplant program consistent with national guidance.

Adhere to OPTN/CMS program and certification standards

Center‑level expectations rely on OPTN/UNOS policies and CMS transplant certification resources cited in the policy; providers should follow those programmatic and certification standards when documenting candidacy.

Policy relies on certified transplant centers (per CMS/OPTN citations)

References include CMS transplant certification resources and OPTN policies, implying reliance on certified transplant centers for evaluation and care, although explicit accreditation requirements are not listed in these chunks.